FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2274014037> ?p ?o ?g. }

• W2274014037 abstract "Abstract Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative option for the treatment of a variety of hematological diseases. However, high incidences of graft versus host disease (GVHD) and tumor relapse remain as major hurdles to this approach. While recent advances in transplant preparation and prophylactic regimens have lowered the incidence of acute GVHD, chronic GVHD (cGVHD) still remains a major cause of long-term morbidity and mortality. Recent studies have suggested that post-translation modifications (PTMs) may serve as therapeutic targets during GVHD. PTMs of proteins are important pathways that confer biochemical alterations, such as acetylation, phosphorylation, and ubiquitination. Targeting PTMs by using small molecular inhibitors has demonstrated potent anti-tumor effects, as well as immune modulatory properties. We have previously shown that bortezomib, an inhibitor of PTMs pathways, can successfully ameliorate sclerodermatous cGVHD responses in both preclinical and clinical studies. Here we reported a new small molecular targeting agent, MLN4924, a selective inhibitor of NEDD8-activating enzyme, on the treatment of cGVHD. MLN4924 is a selective inhibitor of NEDD8-activating enzyme and has been shown to be well tolerated at higher doses and exhibit potent anti-tumor activity in murine models and in early clinical trials. Furthermore, MLN4924 can suppress dendritic cell functions, as well as their production of proinflammatory cytokines during allogeneic responses. Due to these findings, we sought to test the treatment effects of MLN4924 on cGVHD responses. To investigate this, we utilized a minor MHC mismatch murine model by transferring donor B10.D2 (H-2d) cells into BALB/c (H-2d) recipients. MLN4924 or vehicle control (10% 2-hydroxy-propyl-beta cyclodextrin) was injected intraperitoneally on day 20, the point at which skin sclerodermatous cGVHD is initiated. Compared with the vehicle groups, animals that received either bortezomib (0.1 mg/kg) or MLN4924 (20 mg/kg) developed significantly less cGVHD, as determined by clinical scores (2.34±0.34 versus 1.03±0.37 versus 0.8±0.14, respectively; P <0.01). Surprisingly, a preventive approach started from either day 0 or day 10 post-HSCT resulted in higher cGVHD scores compared to early therapeutic interventions, started from Day 20, (3.3 and 2.37± 0.18 versus 0.8±0.14, respectively). The temporally dependent efficacy of MLN4924 suggests that PTMs may play a suppressive role in the early development of cGVHD pathogenesis while worsening cGVHD response as a prevention treatment. Flow cytometric analysis revealed a significant reduction in the total number of macrophages and dendritic cells with MLN4924 treatment starting on day 20, while no significant changes were noticed in T cell subpopulations. Similarly, MLN4924 can successfully inhibit mixed lymphocyte reactions (MLR) in vitro. Importantly, a reduction in the total number of plasma cells, a major source of autoantibody production, was also observed. Together these data suggest that inhibition of neddylation with small molecules, such as MLN4924, can be used as a new approach for the treatment of patients with sclerodermatous cGVHD, while potentially maintaining graft versus tumor effects through preserving T cell populations. Disclosures No relevant conflicts of interest to declare." @default.
• W2274014037 created "2016-06-24" @default.
• W2274014037 creator A5010903477 @default.
• W2274014037 creator A5021579716 @default.
• W2274014037 creator A5022992760 @default.
• W2274014037 creator A5042070203 @default.
• W2274014037 creator A5056942549 @default.
• W2274014037 creator A5079900226 @default.
• W2274014037 creator A5089041781 @default.
• W2274014037 date "2014-12-06" @default.
• W2274014037 modified "2023-09-28" @default.
• W2274014037 title "Therapeutic Effects of MLN4924 on Sclerodermatous Chronic Graft Versus Host Disease" @default.
• W2274014037 doi "https://doi.org/10.1182/blood.v124.21.3816.3816" @default.
• W2274014037 hasPublicationYear "2014" @default.
• W2274014037 type Work @default.
• W2274014037 sameAs 2274014037 @default.
• W2274014037 citedByCount "0" @default.
• W2274014037 crossrefType "journal-article" @default.
• W2274014037 hasAuthorship W2274014037A5010903477 @default.
• W2274014037 hasAuthorship W2274014037A5021579716 @default.
• W2274014037 hasAuthorship W2274014037A5022992760 @default.
• W2274014037 hasAuthorship W2274014037A5042070203 @default.
• W2274014037 hasAuthorship W2274014037A5056942549 @default.
• W2274014037 hasAuthorship W2274014037A5079900226 @default.
• W2274014037 hasAuthorship W2274014037A5089041781 @default.
• W2274014037 hasConcept C126322002 @default.
• W2274014037 hasConcept C164027704 @default.
• W2274014037 hasConcept C203014093 @default.
• W2274014037 hasConcept C2776364478 @default.
• W2274014037 hasConcept C2776914184 @default.
• W2274014037 hasConcept C2777478702 @default.
• W2274014037 hasConcept C2778367456 @default.
• W2274014037 hasConcept C2779972918 @default.
• W2274014037 hasConcept C2911091166 @default.
• W2274014037 hasConcept C502942594 @default.
• W2274014037 hasConcept C71924100 @default.
• W2274014037 hasConcept C8891405 @default.
• W2274014037 hasConceptScore W2274014037C126322002 @default.
• W2274014037 hasConceptScore W2274014037C164027704 @default.
• W2274014037 hasConceptScore W2274014037C203014093 @default.
• W2274014037 hasConceptScore W2274014037C2776364478 @default.
• W2274014037 hasConceptScore W2274014037C2776914184 @default.
• W2274014037 hasConceptScore W2274014037C2777478702 @default.
• W2274014037 hasConceptScore W2274014037C2778367456 @default.
• W2274014037 hasConceptScore W2274014037C2779972918 @default.
• W2274014037 hasConceptScore W2274014037C2911091166 @default.
• W2274014037 hasConceptScore W2274014037C502942594 @default.
• W2274014037 hasConceptScore W2274014037C71924100 @default.
• W2274014037 hasConceptScore W2274014037C8891405 @default.
• W2274014037 hasLocation W22740140371 @default.
• W2274014037 hasOpenAccess W2274014037 @default.
• W2274014037 hasPrimaryLocation W22740140371 @default.
• W2274014037 hasRelatedWork W1997665745 @default.
• W2274014037 hasRelatedWork W2005485279 @default.
• W2274014037 hasRelatedWork W2096644943 @default.
• W2274014037 hasRelatedWork W2099180934 @default.
• W2274014037 hasRelatedWork W2176740545 @default.
• W2274014037 hasRelatedWork W2232344896 @default.
• W2274014037 hasRelatedWork W2346824432 @default.
• W2274014037 hasRelatedWork W2460642271 @default.
• W2274014037 hasRelatedWork W2473655105 @default.
• W2274014037 hasRelatedWork W2535778303 @default.
• W2274014037 hasRelatedWork W2546443007 @default.
• W2274014037 hasRelatedWork W2550090195 @default.
• W2274014037 hasRelatedWork W2551155978 @default.
• W2274014037 hasRelatedWork W2595755981 @default.
• W2274014037 hasRelatedWork W2890415894 @default.
• W2274014037 hasRelatedWork W2913780683 @default.
• W2274014037 hasRelatedWork W3001648260 @default.
• W2274014037 hasRelatedWork W3006254910 @default.
• W2274014037 hasRelatedWork W3014644237 @default.
• W2274014037 hasRelatedWork W3200838393 @default.
• W2274014037 isParatext "false" @default.
• W2274014037 isRetracted "false" @default.
• W2274014037 magId "2274014037" @default.
• W2274014037 workType "article" @default.